Biological optimization of simultaneous boost on intra-prostatic lesions (DILs): Sensitivity to TCP parameters

Physica Medica

Volumn 29, Issue 6, 2013, Pages 592-598

  Azzeroni, R ^a   Maggio, A ^a   Fiorino, C ^a   Mangili, P ^a   Cozzarini, C ^a   De Cobelli, F ^a   Di Muzio, N G ^a   Calandrino, R ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Biological optimization; NTCP; Prostate radiotherapy; TCP

Indexed keywords

ANALYTICAL PARAMETERS; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; DOMINANT INTRA PROSTATIC LESION; FEASIBILITY STUDY; HIGH RISK PATIENT; HUMAN; MALE; NORMAL TISSUE COMPLICATION PROBABILITY; ONCOLOGICAL PARAMETERS; ORGANS AT RISK; PROCESS OPTIMIZATION; PROSTATE CANCER; PROSTATE DISEASE; RADIATION DOSE; RADIOSENSITIVITY; RECTUM; TUMOR CONTROL PROBABILITY;

PERU TOMATO MOSAIC VIRUS;

BIOLOGICAL OPTIMIZATION; NTCP; PROSTATE RADIOTHERAPY; TCP;

HUMANS; MALE; PROBABILITY; PROSTATIC NEOPLASMS; RADIOBIOLOGY; RADIOTHERAPY DOSAGE; RADIOTHERAPY, COMPUTER-ASSISTED; STATISTICS AS TOPIC; UNCERTAINTY;

EID: 84885952372     PISSN: 11201797     EISSN: 1724191X     Source Type: Journal    
DOI: 10.1016/j.ejmp.2012.10.002     Document Type: Article

References (31)

1. Cellini N., Morganti A.G., Mattiucci G.C., Valentini V., Leone M., Luzi S., et al. Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: implications for conformal therapy planning. Int J Radiat Oncol Biol Phys 2002, 53:595-599.
2. De Meerleer G., Villeirs G., Bral S., Paelinck L., De Gersem W., Dekuyper P., et al. The magnetic resonance detected intraprostatic lesion in prostate cancer: planning and delivery of intensity-modulated radiotherapy. Radiother Oncol 2005, 75:325-333.
3. Housri N., Ning H., Ondos J., Choyke P., Camphausen K., Citrin D., et al. Parameters favourable to intraprostatic radiation dose escalation in men with localized prostate cancer. Int J Radiat Oncol Biol Phys 2011, 80:614-620.
4. Fonteyne V., Villeirs G., Speleers B., De Neve W., De Wagter C., Lumen N., et al. Intensity modulated radiotherapy as primary therapy for prostate cancer: report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion. Int J Radiat Oncol Biol Phys 2008, 72:799-807.
5. Ares C., Popowski Y., Pampallona S., Nouet P., Dipasquale G., Bieri S., et al. Hypofractionated boost with high-dose-rate brachytherapy and open magnetic resonance imaging-guided implants for locally aggressive prostate cancer: a sequential dose-escalation pilot study. Int J Radiat Oncol Biol Phys 2009, 75:656-663.
6. Pickett B., Vigneault E., Kurhanewicz J., Verhey L., Roach M. Static field intensity modulation to treat a dominant intra-prostatic lesion to 90 Gy compared to seven field 3-dimensional radiotherapy. Int J Radiat Oncol Biol Phys 1999, 44:921-929.
7. Shaffer R., Morris W.J., Moiseenko V., Welsh M., Crumley C., Nakano S., et al. Volumetric modulated arc therapy and conventional intensity-modulated radiotherapy for simultaneous maximal intraprostatic boost: a planning comparison study. Clin Oncol 2009, 21:401-407.
8. Ost P., Speleers B., De Meerleer G., De Neve W., Fonteyne V., Villeirs G., et al. Volumetric arc therapy and intensity-modulated radiotherapy for primary prostate radiotherapy with simultaneous integrated boost to intraprostatic lesion with 6 and 18 MV: a planning comparison study. Int J Radiat Oncol Biol Phys 2011, 79:920-926.
9. Maggio A., Fiorino C., Mangili P., Cozzarini C., de Cobelli F., Cattaneo G.M., et al. Feasibility of safe ultra-high (EQD2>100Gy) dose escalation on dominant intra-prostatic lesions (DILS) by helical tomotherapy. Acta Oncol 2011, 50:25-34.
10. Woodfield C.A., Tung G.A., Grand D.J., Pezzullo J.A., Machan J.T., Renzulli J.F. Diffusion-weighted MRI of peripheral zone prostate cancer: comparison of tumor apparent diffusion coefficient with Gleason score and percentage of tumor on core biopsy. AJR Am J Roentgenol 2010, 194:W316-W322.
11. Seppälä J., Seppänen M., Arponen E., Lindholm P., Minn H. Carbon-11 acetate PET/CT based dose escalated IMRT in prostate cancer. Radiother Oncol 2009, 93:234-240.
12. Groenendaal G., Moman M.R., Korporaal J.G., van Diest P.J., van Vulpen M., Philippens M.E., et al. Validation of functional imaging with pathology for tumor delineation in the prostate. Radiother Oncol 2010, 94:145-150.
13. Kim C.K., Park B.K., Han J.J., Kang T.W., Lee H.M. Diffusion-weighted imaging of the prostate at 3 T for differentiation of malignant and benign tissue in transition and peripheral zones: preliminary results. JComput Assist Tomogr 2007, 31:449-454.
14. Sato C., Naganawa S., Nakamura T., Kumada H., Miura S., Takizawa O., et al. Differentiation of noncancerous tissue and cancer lesions by apparent diffusion coefficient values in transition and peripheral zone of the prostate. JMagn Reson Imaging 2005, 21:258-262.
15. Kumar V., Jagannathan N.R., Kumar R., Das S.C., Jindal L., Thulkar S., et al. Correlation between metabolite ratios and ADC values of prostate in men with increased PSA level. Magn Reson Imaging 2006, 24:541-548.
16. Nivazi M., Bartenstein P., Belka C., Ganswindt U. Choline PET based dose-painting in prostate cancer - modeling of dose effects. Radiat Oncol 2010, 5:23.
17. 11C-choline positron emission tomography scans. Int J Radiat Oncol Biol Phys 2012, 83(5):e691-e696.
18. Van den Bergh L., Koole M., Isebaert S., Joniau S., Deroose C.M., Oyen R., et al. Is there an additional value of 11C-Choline PET-CT to T2-weighted MRI images in the localization of intraprostatic tumor nodules?. Int J Radiat Oncol Biol Phys 2012, 83:1486-1492.
19. Kim Y., Tomè W.A. On the impact of functional imaging accuracy on selective boosting IMRT. Phys Med 2009, 25:12-24.
20. Raysearch Laboratories Radiobiological evaluation and optimization of treatment plans with RayBiology 2007.
21. Niemierko A. Reporting and analyzing dose distributions: a concept of equivalent uniform dose. Med Phys 1997, 24:103-110.
22. Levegrün S., Jackson A., Zelefsky M.J., Venkatraman E.S., Skwarchuk M.W., Schlegel W., et al. Risk group dependence of dose-response for biopsy outcome after threedimensional conformal radiation therapy of prostate cancer. Radiother Oncol 2002, 63:11-26.
23. Nahum A.E., Movsas B., Horwitz E.M., Stobbe C.C., Chapman J.D. Incorporating clinical measurements of hypoxia into tumor local control modelling of prostate cancer: implications for the α/β ratio. Int J Radiat Oncol Biol Phys 2003, 57:391-401.
24. Peeters S.T., Hoogeman M.S., Heemsbergen W.D., Hart A.A., Koper P.C., Lebesque J.V. Rectal bleeding, fecal incontinence and high stool frequency after conformal radiotherapy for prostate cancer: normal tissue complication probability modelling. Int J Radiat Oncol Biol Phys 2006, 66:11-19.
25. Michalski J.M., Gay H., Jackson A., Tucker S.L., Deasy J.O. Radiation dose-volume effects in radiation-induced rectal injury. Int J Radiat Oncol Biol Phys 2010, 76(3 Suppl):S123-S129.
26. Agren-Cronqvist A, PhD Thesis, Stockolm University, Stockolm, Sweden; 1995.
27. Pucar D., Hricak H., Shukla-Dave A., Kuroiwa K., Drobnjak M., Eastham J., et al. Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor: magnetic resonance imaging and step-section pathology evidence. Int J Radiat Oncol Biol Phys 2007, 69:62-69.
28. Turaka A., Buyyounouski M.K., Hanlon A.L., Horwitz E.M., Greenberg R.E., Movsas B. Hypoxic prostate/muscle Po2 ratio predicts for outcome in patients with localized prostate cancer: long-term results. Int J Radiat Oncol Biol Phys 2012, 82:e433-e439.
29. Fiorino C., Valdagni R., Rancati T., Sanguineti G. Dose-volumes effects for normal tissues in external radiotherapy: pelvis. Radiother Oncol 2009, 93:153-167.
30. Cahlon O., Zelefsky M.J., Shippy A., Chan H., Fuks Z., Yamada Y., et al. Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes. Int J Radiat Oncol Biol Phys 2008, 71:330-337.
31. Tomè W.A., Fowler J.F. On cold spots in tumor subvolumes. Med Phys 2002, 29:1590-1598.